ADXN Stock Overview Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Addex Therapeutics Ltd Competitors Price History & Performance
Summary of share price highs, lows and changes for Addex Therapeutics Historical stock prices Current Share Price CHF 0.057 52 Week High CHF 0.26 52 Week Low CHF 0.045 Beta 1.89 1 Month Change -7.74% 3 Month Change -14.88% 1 Year Change 24.35% 3 Year Change -94.28% 5 Year Change -96.59% Change since IPO -99.92%
Recent News & Updates Addex Therapeutics Ltd to Report Fiscal Year 2024 Results on Mar 24, 2025
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 24
New major risk - Revenue size Oct 16
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Oct 01
Addex Therapeutics Ltd to Report First Half, 2024 Results on Sep 16, 2024 Sep 10
Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration Aug 27 See more updates Addex Therapeutics Ltd to Report Fiscal Year 2024 Results on Mar 24, 2025
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 24
New major risk - Revenue size Oct 16
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Oct 01
Addex Therapeutics Ltd to Report First Half, 2024 Results on Sep 16, 2024 Sep 10
Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration Aug 27
Addex Therapeutics Ltd Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium Jul 15
New major risk - Financial position Jun 09
Addex Therapeutics Ltd, Annual General Meeting, Jun 28, 2024 Jun 08
No longer forecast to breakeven May 31
Full year 2023 earnings: EPS and revenues exceed analyst expectations Apr 18
New major risk - Revenue and earnings growth Apr 18
No longer forecast to breakeven Apr 18
Addex Therapeutics Ltd to Report Fiscal Year 2023 Results on Apr 18, 2024 Apr 11
Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders Apr 05
New major risk - Shareholder dilution Mar 30 Addex Therapeutics Ltd has filed a Follow-on Equity Offering in the amount of $2.15 million. Jan 31
Addex Therapeutics Ltd to Report Q3, 2024 Results on Nov 11, 2024
Co-Founder recently bought CHF911k worth of stock Dec 01
Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint Nov 30
Addex Therapeutics' ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients Nov 15
Addex Regains Nasdaq Listing Compliance Nov 08
New minor risk - Profitability Oct 10
Consensus revenue estimates increase by 31% Sep 06
Addex Therapeutics Announces Data Published in Brain Sep 05
New major risk - Market cap size Aug 16
Second quarter 2023 earnings released: CHF0.04 loss per share (vs CHF0.19 loss in 2Q 2022) Aug 13 Addex Therapeutics Ltd announced that it has received CHF 2.7 million in funding from Indivior PLC Aug 04
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder Jul 25
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency May 19
First quarter 2023 earnings released: CHF0.04 loss per share (vs CHF0.15 loss in 1Q 2022) May 12
Addex Therapeutics Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study May 11
Insufficient new directors Apr 02
No longer forecast to breakeven Mar 31
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely Mar 03
Addex Regains Nasdaq Listing Compliance Feb 10 Addex Therapeutics Ltd to Report Fiscal Year 2022 Results on Mar 13, 2023
No longer forecast to breakeven Nov 16
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Nov 03
Consensus revenue estimates fall by 27% Aug 31 Addex Therapeutics Ltd announced that it has received funding from Armistice Capital LLC Jul 28
Addex Therapeutics Ltd announced that it expects to receive funding from Armistice Capital LLC Jul 23
No longer forecast to breakeven Jun 30
Consensus forecasts updated Jun 29
Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate Jun 17
Consensus forecasts updated May 28
Addex Therapeutics Ltd Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study May 27
No longer forecast to breakeven May 25
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely May 11
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 06
Price target decreased to CHF1.40 Apr 27
Forecast to breakeven in 2024 Apr 27
Addex Therapeutics Ltd Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study Apr 13
Addex Therapeutics Ltd Expands Pipeline with Selective M4 Positive Allosteric Modulator Program Apr 06
Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022 Mar 31
Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022 Mar 29
Consensus revenue estimates fall by 64% Mar 17
Price target decreased to CHF1.40 Mar 12
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 11
Forecast to breakeven in 2023 Jan 11
Addex Therapeutics Ltd announced that it has received CHF 5.427937 million in funding from Armistice Capital LLC Dec 22
Addex Therapeutics Ltd announced that it expects to receive CHF 5.427937 million in funding from Armistice Capital LLC Dec 19
Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth? Nov 23
Third quarter 2021 earnings released: CHF0.11 loss per share (vs CHF0.12 loss in 3Q 2020) Nov 06
Addex Therapeutics Ltd Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm Oct 01
Director Jason Nunn has joined 5th company board Sep 02
Director Jason Nunn has joined 5th company board Sep 02
Director Jason Nunn has joined 5th company board Sep 02
Director Jason Nunn has joined 5th company board Sep 02
Second quarter 2021 earnings released: CHF0.14 loss per share (vs CHF0.12 loss in 2Q 2020) Aug 06 Shareholder Returns ADXN CH Biotechs CH Market 7D -1.0% 6.7% 1.1% 1Y 24.3% 105.8% 2.6%
See full shareholder returns
Return vs Market: ADXN exceeded the Swiss Market which returned 2.6% over the past year.
Price Volatility Is ADXN's price volatile compared to industry and market? ADXN volatility ADXN Average Weekly Movement 12.2% Biotechs Industry Average Movement 13.2% Market Average Movement 3.3% 10% most volatile stocks in CH Market 7.8% 10% least volatile stocks in CH Market 1.6%
Stable Share Price: ADXN's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: ADXN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Show more Addex Therapeutics Ltd Fundamentals Summary How do Addex Therapeutics's earnings and revenue compare to its market cap? ADXN fundamental statistics Market cap CHF 5.62m Earnings (TTM ) -CHF 12.67m Revenue (TTM ) CHF 592.36k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ADXN income statement (TTM ) Revenue CHF 592.36k Cost of Revenue CHF 6.69m Gross Profit -CHF 6.09m Other Expenses CHF 6.58m Earnings -CHF 12.67m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 24, 2025
Earnings per share (EPS) -0.13 Gross Margin -1,028.84% Net Profit Margin -2,139.51% Debt/Equity Ratio 0%
How did ADXN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 00:33 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Addex Therapeutics Ltd is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Leonildo Delgado Baader Helvea Equity Research Bob Pooler Bank am Bellevue Silvia Schanz Bank Vontobel AG
Show 8 more analysts 
